111 (NASDAQ:YI) Given “Sell (D-)” Rating at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of 111 (NASDAQ:YI) in a research report sent to investors on Saturday morning,Weiss Ratings reports.

111 Trading Up 3.5 %

YI stock opened at $10.49 on Friday. The stock has a market capitalization of $89.71 million, a P/E ratio of -2.62 and a beta of 0.46. 111 has a 12 month low of $4.15 and a 12 month high of $14.10. The firm has a 50-day moving average price of $7.22 and a 200-day moving average price of $7.33.

111 (NASDAQ:YI) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $527.14 million for the quarter.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. FIL Ltd bought a new position in 111 during the 4th quarter worth approximately $450,000. Napean Trading & Investment Co Singapore PTE Ltd acquired a new stake in shares of 111 during the 4th quarter worth approximately $245,000. Finally, JPMorgan Chase & Co. grew its position in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after buying an additional 305,339 shares during the period. Institutional investors own 21.32% of the company’s stock.

111 Company Profile

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.